---
schema_version: "secwatch.filing_event.v1"
accession: "0001129928-26-000074"
form_type: "8-K"
ticker: "ONCY"
cik: "0001129928"
company_name: "ONCOLYTICS BIOTECH INC"
filed_at: "2026-10-20T13:37:52+00:00"
generated_at: "2026-10-20T13:39:09.633376+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Oncolytics ESMO abstract details 60-patient REO 033 colorectal study; prior REO 022 showed 17-month PFS vs 6

## Summary
- REO 033 randomized, open-label Phase 2 study enrolls 30 patients per arm: pelareorep + FOLFIRI + bevacizumab vs FOLFIRI + bevacizumab in 2L RAS-mutant MSS mCRC.
- Primary endpoint is objective response rate; secondary endpoints include OS, PFS, disease control rate, duration of response, safety/tolerability, and biomarker sampling.
- Recent FDA interactions enable pivotal Part B expansion of REO 033, potentially supporting accelerated approval based on ORR and full approval based on PFS.
- Prior REO 022 in 2L KRAS-mutant MSS mCRC more than doubled ORR, median PFS, OS and DOR versus historical FOLFIRI/bevacizumab; headline cites 17-month PFS vs 6 months.
- Abstract 994eTiP e-poster at ESMO Congress 2026; lead investigator Sanjay Goel cited conviction pelareorep can meaningfully impact patients.

## SEC filing metadata
- accession: 0001129928-26-000074
- form_type: 8-K
- ticker: ONCY
- cik: 0001129928
- company_name: ONCOLYTICS BIOTECH INC
- filed_at: 2026-10-20T13:37:52+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1129928/000112992826000074/0001129928-26-000074-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1129928/000112992826000074/oncy-20261020.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001129928-26-000074
- JSON: https://secwatch.observer/filing/0001129928-26-000074.json
- Plain text: https://secwatch.observer/filing/0001129928-26-000074.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.